Physician profile
Daniel T Lee
NPI 1861472367
$189,971.06
in general payments reported to CMS, 2019-2025
40 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $9,215 · 2021: $47K · 2022: $31K · 2023: $34K · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Food and Beverage: $5,458 · Travel and Lodging: $2,856 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,970.25 |
| Food and Beverage | $5,458.04 |
| Travel and Lodging | $2,856.04 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102,819.09 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $61,127.35 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $15,628.02 | 2019-2024 | Farxiga, Wainua |
| Medtronic Vascular, INC. | $1,991.72 | 2019 | |
| Philips North America LLC | $1,281.45 | 2025 | Coronary Other |
| Novartis Pharmaceuticals Corporation | $1,043.74 | 2019-2025 | |
| Abbott Laboratories | $964.71 | 2019-2024 | Optis, Coroflow |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.79 | 2021-2024 | Jardiance |
| Pfizer INC. | $538.13 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $476.05 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $394.38 | 2019-2025 | Camzyos, Eliquis |
| Edwards Lifesciences Corporation | $364.33 | 2019-2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $322.82 | 2019-2024 | Lifevest |
| Astellas Pharma US INC | $299.12 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $207.38 | 2021-2024 | Opsumit, Uptravi |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $206.72 | 2024-2025 | Impella |
| Shockwave Medical, INC | $199.64 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Merck Sharp & Dohme LLC | $182.81 | 2021-2024 | Verquvo |
| Lexicon Pharmaceuticals, INC. | $172.42 | 2023-2024 | Inpefa |
| Kowa Pharmaceuticals America, INC. | $172.34 | 2019-2023 | Livalo |
| Amarin Pharma, INC. | $152.69 | 2020-2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $144.98 | 2021-2023 | Arcalyst |
| Terumo Medical Corporation | $125.14 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $121.05 | 2019 | |
| Esperion Therapeutics, INC. | $80.79 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $68.29 | 2019-2023 | |
| Ekos Corporation | $54.01 | 2019 | |
| Lundbeck LLC | $45.37 | 2020 | |
| Inari Medical, INC. | $32.36 | 2019 | |
| Kestra Medical Technology Services, INC. | $25.57 | 2024 | Assure Wcd |
| Osprey Medical INC | $24.33 | 2019-2020 | |
| Amryt Pharma Holdings Ltd | $21.32 | 2021 | |
| Novo Nordisk INC | $20.17 | 2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $16.85 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.79 | 2022 | |
| Teleflex LLC | $15.77 | 2021 | |
| Baylis Medical Company INC | $13.57 | 2021 | |
| Zoll Circulation INC | $10.00 | 2025 | Therox Ds2 Console, Catheter, Downstream Cartridge |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.